检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:宋英莉[1] 王洪一[1] 马书丹 徐志山 陶凯[1] SONG Ying-li, WANG Hong-yi, MA Shu-dan, XU Zhi-shan, TAO Kai.(Department of Plastic Surgery, The General Hospital of Shenyang Military Region, Shenyang 110840, Chin)
机构地区:[1]沈阳军区总医院整形外科,辽宁沈阳110840
出 处:《中国美容整形外科杂志》2018年第5期297-300,共4页Chinese Journal of Aesthetic and Plastic Surgery
摘 要:目的探究防己诺林碱对增生性瘢痕的抑制作用。方法提取原代瘢痕组织成纤维细胞,分别用DMSO(对照组),10、20、40μmol/L的防己诺林碱处理成纤维细胞24 h后,通过MTT实验检测对其增殖能力的影响;通过流式细胞术及Hochest33258染色检测对其增殖、凋亡能力的影响;通过western blot和real time PCR检测防己诺林碱对瘢痕组织成纤维细胞中Cyclin D1和Bcl-2表达水平的影响。结果 10、20、40μmol/L的防己诺林碱作用瘢痕组织成纤维细胞24 h后,细胞的抑制率分别为(21.32±4.87)%、(27.13±1.71)%和(29.86±5.59)%,与对照组相比差异均具有统计学意义;防己诺林碱还可抑制细胞周期进程,促进其凋亡;Western blot和real time PCR检测结果显示,防己诺林碱可抑制Cyclin D1和Bcl-2在瘢痕组织成纤维细胞中的表达。结论防己诺林碱可抑制瘢痕组织成纤维细胞的生长。Objective To explore the inhibitory effect of fangchinoline on hypertrophic scars. Methods After the primary hypertrophic scar fibroblasts were extracted, MTT assay was used to detect the effect of 10 μmol/L, 20 μmol/L and 40 μmol/L of fangchinoline on cells. Flow cytometry and Hochest 33258 staining were used to detect the effect of fangchinoline on cell proliferation and apoptosis. The effect of fangchinoline on Cyclin D1 and Bcl-2 in hypertrophic scar fibroblasts was detected by western blot and real time PCR.Results Compared with the DMSO control group, the inhibition rate of 10 μmol/L, 20 μmol/L and 40 μmol/L of cells treated with fanchinoline for 24 h were(21.32±4.87)%,(27.13±1.71)% and(29.86±5.59)%. Fangchinoline was capable of inhibiting the growth of hypertrophic scar fibroblasts and the cell cycle and promote cell apoptosis. Western blot and real time PCR results showed fangchinoline could inhibit the expression of Cyclin D1 and Bcl-2. Conclusion Fangchinoline can inhibit the growth of hypertrophic scar fibroblasts.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15